Dutch precision-medicine company spun out of Philips with OncoSIGNal pathway profiling.
| Date | Round | Amount |
|---|---|---|
| Apr 2022 | Series A Eindhoven medtech InnoSIGN raised an 8M dollar Series A from Casdin Capital, Thuja Capital and BOM to spin out from Philips and develop its OncoSIGNal tests. | $7.3M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.